Added Value of Soluble Tumor Necrosis Factor-α Receptor 1 as a Biomarker of ESRD Risk in Patients With Type 1 DiabetesCarol Forsblom, Merlin C. Thomas, Lena M. Thorn et al.|Diabetes Care|2014Cited by 49
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Peter Dubsky, Margaretha Rudas et al.|Clinical Cancer Research|2021Cited by 3
Table S1 from The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Peter Dubsky, Margaretha Rudas et al.|Unknown|2023Cited by 0